<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Frontal fibrosing alopecia: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Frontal fibrosing alopecia: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Frontal fibrosing alopecia: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oma N Agbai, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Hordinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3023803278"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Frontal fibrosing alopecia (FFA) is a lymphocytic cicatricial (scarring) alopecia that classically presents with the progressive development of a symmetric, band-like patch of alopecia involving the frontal hairline  (<a class="graphic graphic_picture graphicRef127007 graphicRef127013 graphicRef101628 graphicRef90010" href="/z/d/graphic/127007.html" rel="external">picture 1A-D</a>). FFA most frequently occurs in postmenopausal women and is postulated to be a subtype of lichen planopilaris based upon the presence of similar histopathologic findings. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris"</a>.)</p><p>Most patients with FFA desire treatment due to the chronic and progressive nature of the disease and the risk for permanent and disfiguring alopecia. However, data on the local and systemic therapies for FFA are limited, and high-quality trials are lacking, precluding conclusions on the best approach to therapy. Moreover, interpretation of the available data is complicated by the frequent use of combination therapy and the potential for spontaneous cessation of hairline recession.</p><p>The pathogenesis, clinical manifestations, and diagnosis of FFA are discussed separately. Overviews of lichen planopilaris and the evaluation of patients with hair loss are also provided separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128536.html" rel="external">"Frontal fibrosing alopecia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p></p><p class="headingAnchor" id="H2655409646"><span class="h1">GOALS</span><span class="headingEndMark"> — </span>The primary goal of treatment is disease stabilization (the cessation of hairline recession and further hair loss). Additional desired effects include the resolution of other signs of disease activity, including perifollicular erythema, perifollicular hyperkeratosis, and associated symptoms. Although some studies have reported regrowth of hair with treatment, regrowth is usually limited or absent due to follicular scarring. (See <a class="local">'General approach'</a> below.)</p><p class="headingAnchor" id="H2655477617"><span class="h1">ASSESSMENT OF RESPONSE</span><span class="headingEndMark"> — </span>Different methods have been utilized to assess the response of FFA to treatment. </p><p>Assessment for cessation of hairline recession, the primary treatment goal, is essential and can be performed via serial measurements of the distance between the hairline and facial landmarks [<a href="#rid1">1</a>]. Typical landmarks include the glabella and bilateral outer canthi. In our experience, serial clinical photographs are a valuable supplement to measurements, providing visual documentation of disease progression.</p><p>The response of other findings suggestive of disease activity can be routinely assessed through the patient history and physical examination. The presence of symptoms (pruritus, burning, or pain) and physical signs of disease activity (perifollicular erythema or scale) should be assessed at follow-up visits.</p><p>Scoring systems have also been used to assess severity and response to treatment, primarily in the setting of specialty clinics and clinical studies. Examples include the Lichen Planopilaris Activity Index (LPPAI) and the Frontal Fibrosing Alopecia Severity Score (FFASS). The LPPAI includes assessment of symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema, perifollicular scale), anagen hair shedding (assessed via hair pull test), and spreading [<a href="#rid2">2</a>]. The FFASS includes assessment of hairline recession, eyebrow hair loss, perifollicular inflammation, pruritus, and pain [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3609369765"><span class="h1">WHO TO TREAT</span><span class="headingEndMark"> — </span>It is generally accepted that treatment is appropriate for patients with signs supportive of active FFA, including progressing hair loss, clinical signs of inflammation (eg, perifollicular erythema or scale), or symptoms (eg, pruritus, burning, or pain).</p><p>The best approach to patients without evidence of progressing hair loss, clinical signs of inflammation, or symptoms is less clear because truly inactive disease is considered unlikely to benefit from medical treatments [<a href="#rid4">4</a>]. We typically offer treatment to all patients with FFA at the time of initial presentation because of the potential for subtle, unrecognized disease activity (eg, slow hair loss not evident to the patient).</p><p>If an absence of recent progression is confirmed (eg, via review of clinical measurements and clinical reports that support stable disease for at least 12 months) and other signs of active disease are absent, we do not initiate treatment specifically for FFA. Treatment for concomitant disorders that may also cause hair loss, such as androgenic alopecia, can still be initiated, and periodic clinical follow-up should occur to facilitate early detection of recurrences of disease activity.</p><p class="headingAnchor" id="H644558095"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>Treatments for FFA include a wide variety of medications that aim to suppress the damaging inflammatory process or that may work through other mechanisms. Because of the paucity of data to guide the treatment of FFA, approaches to treatment differ. Our approach to FFA is reviewed here; other approaches may be reasonable.</p><p class="headingAnchor" id="H2148922851"><span class="h2">Treatment selection</span><span class="headingEndMark"> — </span>Common initial therapies for FFA include local therapies (topical corticosteroids, topical calcineurin inhibitors, intralesional corticosteroid injections, topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>) and systemic therapies (oral 5-alpha reductase inhibitors [5-ARIs], <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, and oral tetracyclines). Rarely, systemic glucocorticoids are prescribed in an attempt to slow rapid hair loss. (See <a class="local">'Rapidly progressing disease'</a> below.)</p><p>Our typical initial treatment regimen consists of the combination of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A super high- or high-potency topical corticosteroid applied daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermittent intralesional corticosteroid injections administered approximately every eight weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> 5% solution or foam applied daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic therapy with a 5-ARI, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, or a tetracycline-class antibiotic for patients with progressing disease who desire aggressive treatment</p><p></p><p>Selection of a systemic therapy is based upon consideration of patient-specific contraindications and preferences. We tend to use a 5-ARI as the first systemic therapy for patients without contraindications to this form of therapy. (See <a class="local">'Systemic therapies'</a> below and <a class="local">'5-alpha reductase inhibitors'</a> below.)</p><p>Approaches to the initiation of systemic therapy for FFA differ. Because of the potential for permanent hair loss, we have a low threshold for starting systemic therapy in patients who are experiencing active progression of hair loss and who desire aggressive treatment. Other clinicians opt to delay systemic therapy until there is an inadequate response to local treatment or reserve systemic therapy for patients presenting with certain features, such as prominent hairline recession, prominent perifollicular erythema, or prominent symptoms (eg, pruritus, burning, tenderness) [<a href="#rid1">1,5</a>].</p><p>Following stable resolution of signs of disease activity, topical and systemic treatment can be cautiously reduced to the lowest amount of therapy necessary to maintain improvement. (See <a class="local">'Approach after achievement of stabilization'</a> below.)</p><p>Patients who fail to respond well to an initial treatment course or cannot tolerate an initial treatment are typically transitioned to other combinations of the initial therapies. Refractory disease may be treated with oral retinoids, immunosuppressive drugs, or other therapies. (See <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H1212310702"><span class="h2">Local therapies</span><span class="headingEndMark"> — </span>Common initial local therapies for FFA include topical corticosteroids, topical calcineurin inhibitors, intralesional corticosteroid injections, and topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>. Local treatments should be administered to the area of alopecia, adjacent hair-bearing regions, and symptomatic areas. </p><p class="headingAnchor" id="H2922286064"><span class="h3">Topical corticosteroids and calcineurin inhibitors</span><span class="headingEndMark"> — </span>Topical corticosteroids and topical calcineurin inhibitors (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a>) are thought to suppress the damaging inflammatory process in FFA:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection</strong> – Topical corticosteroids are often the initial topical immunosuppressants used for FFA, as they are widely available and often less expensive than topical calcineurin inhibitors. However, the potential for corticosteroid-induced skin atrophy can limit long-term use of topical corticosteroids. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">Topical calcineurin inhibitor use is often begun when patients develop signs of skin atrophy or as a measure to prevent atrophy when long-term, frequent use of topical corticosteroid therapy appears necessary for maintaining disease control. However, some clinicians consider topical calcineurin inhibitors the preferred initial topical immunosuppressants for FFA based upon a desire to avoid risk for corticosteroid-induced skin atrophy in cosmetically sensitive areas [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and efficacy</strong> – Topical corticosteroid therapy typically involves the application of a super high-potency or high-potency (groups 1 or 2) topical corticosteroid daily to the affected area  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>). Daily treatment is continued until hair loss has been stabilized. (See <a class="local">'Approach after achievement of stabilization'</a> below.)</p><p></p><p class="bulletIndent1">In our experience, at least partial clinical improvement in disease activity typically occurs within eight weeks. We discontinue treatment after this period if there is no improvement in hair loss or other signs of disease activity.</p><p></p><p class="bulletIndent1">Similarly, topical calcineurin inhibitors (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment or compounded solution, <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream) are applied daily. Topical calcineurin inhibitors may be used to decrease the frequency of topical corticosteroid use (eg, application on alternating weeks or application of the topical calcineurin inhibitor on weekdays and topical corticosteroid on weekends). Reducing the frequency of topical corticosteroid use may decrease risk for corticosteroid-induced skin atrophy.</p><p></p><p class="bulletIndent1">Use of topical corticosteroids and topical calcineurin inhibitors is based upon data from retrospective studies and clinical experience [<a href="#rid1">1</a>]. Responses to treatment appear to vary. In one of the largest retrospective studies to evaluate these treatments, combination therapy with <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate or <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> valerate with <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream was associated with subjective improvement or disease stabilization in 31 of 48 treated patients (65 percent) followed for a median duration of 20 months [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– Cutaneous atrophy, acneiform eruptions, suppression of the hypothalamic-pituitary axis, and other adverse effects of topical corticosteroids are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1">Topical calcineurin inhibitors may be associated with transient burning, erythema, or pruritus after application. Although the US Food and Drug Administration issued warnings in 2005 regarding a possible link between topical calcineurin inhibitor use and cancer, a causal relationship has not been established. (See  <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p></p><p class="headingAnchor" id="H3898838992"><span class="h3">Intralesional corticosteroid injections</span><span class="headingEndMark"> — </span>Intralesional injection of corticosteroids aims to deliver corticosteroids directly into the dermis to suppress perifollicular inflammation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and efficacy</strong> – Intralesional corticosteroid injections are commonly employed in the treatment of inflammatory cicatricial alopecias. A disadvantage of this intervention is the discomfort associated with treatment. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection"</a>.)</p><p></p><p class="bulletIndent1">Intralesional corticosteroid injections for FFA are typically performed with 2.5 to 10 mg/mL of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide and performed every four to eight weeks. Injections are placed throughout the area of alopecia and the hair-bearing posterior margin as well as sites demonstrating perifollicular erythema, scale, or symptoms related to FFA (eg, pruritus, burning, tenderness).</p><p></p><p class="bulletIndent1">We generally treat with 5 or 10 mg/mL <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide injections every eight weeks. At least partial improvement in disease activity is expected within two to three treatments. In patients who exhibit progressive improvement, we continue treatment until clinical signs of disease activity resolve. If no signs of improvement occur after a few treatments, we discontinue injections. (See <a class="local">'Approach after achievement of stabilization'</a> below.)</p><p></p><p class="bulletIndent1">Because the risk for corticosteroid-induced skin atrophy increases with increasing concentrations, some clinicians do not exceed 2.5 mg/mL when treating cosmetically sensitive areas [<a href="#rid6">6</a>]. However, use of 10 mg/mL of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide for eyebrow FFA without the development of cutaneous atrophy has been reported [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Use of intralesional corticosteroid therapy for FFA is based upon retrospective studies and clinical experience [<a href="#rid1">1</a>]. One of the largest studies included 130 patients with FFA treated with intralesional corticosteroid injections every three to six months for an average of eight treatments [<a href="#rid9">9</a>]. Improvement (any regrowth of hair in the hairline) was reported in 44 patients (34 percent), and stabilization of disease (arrest of hairline recession) was noted in 64 patients (49 percent). Many patients also received other treatments.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In addition to skin atrophy, intralesional corticosteroid injections may result in hypopigmentation. Infrequent adverse effects include sterile abscesses and hypothalamic-pituitary axis suppression. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p></p><p class="bulletIndent1">In the event of skin atrophy, intralesional <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> injections should be stopped until the atrophy resolves, which usually takes up to a few months. Limiting the total amount of corticosteroid injected per treatment session may reduce risk for systemic adverse effects. We typically limit the total dose to no more than 20 mg of triamcinolone acetonide per treatment session.</p><p></p><p class="headingAnchor" id="H3886653101"><span class="h3">Topical minoxidil</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> is a common treatment for female and male pattern hair loss that is also frequently used in patients with FFA. The mechanism of action for minoxidil is unknown; effects on male and female pattern hair loss are thought to result from prolongation of the anagen (growth) phase of hair follicles, shortening of the telogen (resting) phase, and induction of enlargement of miniaturized follicles [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/z/d/html/86648.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Management", section on 'Topical minoxidil'</a> and  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and efficacy</strong> – Although often used, data to confirm the efficacy of <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> for FFA are lacking. Proposed rationales for the use of topical minoxidil include cosmetic improvement related to efficacy for coexisting female or male pattern hair loss and the potential for antifibrotic effects of minoxidil to reduce follicular scarring [<a href="#rid11">11</a>]. Some clinicians limit use of minoxidil to patients with evidence of concomitant female or male pattern hair loss [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1">We typically advise patients to apply <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> 5% foam or solution. Women apply minoxidil 5% once daily. Men apply minoxidil 5% twice daily. A noticeable reduction in hair loss is expected within the first four to six months of treatment. Regrowth of hair lost secondary to FFA is not expected. (See <a class="local">'Approach after achievement of stabilization'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Examples of adverse effects of <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> include skin irritation manifesting as erythema and pruritus, initial hair shedding, and facial hypertrichosis. (See  <a class="drug drug_general" href="/z/d/drug information/9617.html" rel="external">"Minoxidil (topical): Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H4216437804"><span class="h2">Systemic therapies</span><span class="headingEndMark"> — </span>Common initial systemic therapies for FFA include 5-ARIs, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, and tetracyclines. There are insufficient data to confirm the efficacy of any of these treatments. The selection of these agents over other systemic drugs used for FFA is based upon reports that suggest benefit and the relatively well-tolerated nature of these therapies.</p><p>Infrequently, systemic glucocorticoid therapy is used in an attempt to stabilize rapidly progressive disease. However, the potential for serious adverse effects precludes routine use of this therapy. (See <a class="local">'Rapidly progressing disease'</a> below.)</p><p class="headingAnchor" id="H2630818320"><span class="h3">General approach</span><span class="headingEndMark"> — </span>Individuals who are not of childbearing potential may be treated with 5-ARIs, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, or a <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>. Treatment with 5-ARIs is contraindicated during pregnancy, and caution is indicated for use in patients who may become pregnant. (See <a class="local">'5-alpha reductase inhibitors'</a> below.)</p><p>Literature support for benefit of these therapies is primarily limited to retrospective studies, and data are insufficient to confirm efficacy of any of these therapies [<a href="#rid1">1</a>]. Selection among these three interventions is based upon consideration of patient-specific contraindications and preferences.</p><p class="headingAnchor" id="H3434917298"><span class="h4">5-alpha reductase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">Finasteride</a> and <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> are used for FFA, although the mechanism through which 5-ARIs might improve FFA is unclear. Dutasteride inhibits both 5-alpha reductase types 1 and 2, making it a more potent 5-ARI than finasteride, which inhibits only 5-alpha reductase type 2. However, greater efficacy of dutasteride for FFA has not been proven.</p><p>Some authors have challenged the use of 5-ARIs for FFA based upon limited evidence for efficacy and the unclear rationale for benefit [<a href="#rid12">12</a>]. It has been proposed that improvement in hair loss may be attributable to positive effects on coexisting androgenetic alopecia:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and efficacy</strong> – Regimens for 5-alpha reductase therapy vary, and the preferred regimens are unclear. Avoidance of 5-ARI therapy during pregnancy is essential. Treatment should not be given to premenopausal individuals of childbearing potential who are unwilling or unable to comply with reliable birth control methods.</p><p></p><p class="bulletIndent1">Dosing for 5-ARIs varies, and the optimal regimen for FFA is unclear. Examples of initial regimens we utilize include 2.5 to 5 mg per day of <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> and 0.5 mg per day of <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a>. We treat for at least four months prior to assessing efficacy (improvement in hair loss) and continue treatment in patients who appear to respond. (See <a class="local">'Approach after achievement of stabilization'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p></p><p class="bulletIndent1">Evidence to support use of 5-ARIs comes from retrospective studies and case reports [<a href="#rid13">13</a>]. In one of the largest studies, a retrospective study that included 111 patients treated with a 5-ARI (often in conjunction with other therapies), treatment with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (2.5 to 5 mg per day) was associated with improvement (any regrowth of hair in the hairline) or stabilization of disease (arrest of hairline recession) in 47 and 53 percent of 102 treated patients, respectively [<a href="#rid9">9</a>]. Among 18 patients given <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> (0.5 mg per week), 44 percent had improvement and 56 percent achieved stabilization.</p><p></p><p class="bulletIndent1">Another retrospective study of 242 females with FFA that included 106 patients treated with only <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> (0.5 mg three times per week) and topical <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> 0.05% foam (twice weekly) found 28 (37 percent) had achieved stabilization of disease after 12 months [<a href="#rid14">14</a>]. The remaining patients experienced continued recession. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of 5-ARIs include abnormalities of genitalia in the male fetus when taken during pregnancy, sexual dysfunction, mood disturbances, and hypotension. Safety data in women are minimal [<a href="#rid15">15</a>]. (See  <a class="drug drug_general" href="/z/d/drug information/8447.html" rel="external">"Finasteride: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/8672.html" rel="external">"Dutasteride: Drug information"</a>.)</p><p></p><p class="bulletIndent1">There is uncertainty regarding the relationship between 5-ARI therapy and high-grade prostate cancer. This is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6949.html" rel="external">"Chemoprevention strategies in prostate cancer", section on '5-Alpha reductase inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H94765546"><span class="h4">Hydroxychloroquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> is postulated to benefit FFA through immunomodulatory properties:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and efficacy</strong> – <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> may be given at a dose of 200 mg twice daily. However, because the maximum daily dose should not exceed 5 mg/kg to minimize the risk for hydroxychloroquine-induced retinopathy, lower doses are necessary for patients weighing less than 80 kg [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Dose adjustment for weight'</a>.)</p><p></p><p class="bulletIndent1">In our experience, responses to <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> often become evident within the first four months of treatment. If there is no response within this period, we proceed to other treatments. (See <a class="local">'Approach after achievement of stabilization'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p></p><p class="bulletIndent1">Use of <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> is based upon retrospective study data [<a href="#rid1">1</a>]. For example, in a retrospective study that included 54 patients treated with hydroxychloroquine (200 to 400 mg per day) alone or in conjunction with other therapies, 8 (15 percent) improved (any regrowth of hair in the hairline), 32 (59 percent) stabilized (arrest of hairline recession), and 12 (22 percent) worsened (progression of hairline recession) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> can cause retinopathy. Baseline and follow-up ophthalmologic examinations are advised for treated patients. (See  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Monitoring for toxicity'</a>.)</p><p></p><p class="bulletIndent1">Examples of additional adverse effects include gastrointestinal distress, skin eruptions, and hematologic toxicity. (See  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H2797559074"><span class="h4">Tetracyclines</span><span class="headingEndMark"> — </span>Benefit of tetracyclines for FFA is postulated to result from anti-inflammatory properties:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and efficacy</strong> – Common treatment regimens for FFA include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily), <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (100 mg twice daily), and <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (500 mg twice daily). Initial signs of response to tetracyclines usually become evident within two months. If there is no improvement within four months, we stop treatment and proceed to other therapies. (See <a class="local">'Approach after achievement of stabilization'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p></p><p class="bulletIndent1">Efficacy data on tetracyclines are limited [<a href="#rid1">1</a>]. Treatment with tetracyclines was documented as demonstrating similar efficacy outcomes as treatment with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> in a retrospective study that included 65 patients given <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and 32 patients treated with hydroxychloroquine; however, the proportion of responders was not reported [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Tetracyclines, particularly <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, can cause photosensitivity. Examples of additional adverse effects of tetracyclines include gastrointestinal distress, esophagitis, and pseudotumor cerebri. <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> may also cause vertigo, skin discoloration, serum sickness, and a lupus-like syndrome. Tetracyclines can cause discoloration of developing teeth and should not be administered to pregnant individuals.</p><p></p><p class="headingAnchor" id="H4011306933"><span class="h1">APPROACH AFTER ACHIEVEMENT OF STABILIZATION</span><span class="headingEndMark"> — </span>Following successful achievement of disease stabilization, treatment can be tapered slowly, as tolerated, usually over several months. We typically do not attempt tapering of systemic therapies until evidence of hair loss progression has been absent for at least four to six months. </p><p>Tapering of topical and intralesional therapies typically involves reducing the frequency of application. For example, topical corticosteroid use may be reduced to every-other-day application for eight weeks, followed by application three times weekly. If disease activity does not recur after two to three months of thrice weekly use, treatment can be discontinued. Tapering of systemic therapies involves dose and/or frequency reductions.</p><p>Close clinical follow-up should continue during tapering; we typically reassess patients two to three months after treatment reductions. Recurrence of disease activity prompts a return to the previously effective regimen.</p><p class="headingAnchor" id="H4043681233"><span class="h1">RAPIDLY PROGRESSING DISEASE</span><span class="headingEndMark"> — </span>Oral glucocorticoids are not recommended for the routine treatment of FFA but are infrequently used in an attempt to stabilize rapidly progressive disease (eg, &gt;1 cm hairline recession over a two-month period). Treatment with oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 mg per day for one week and then tapered by 5 mg per week for eight weeks has been suggested by some authors and is an approach that we consider reasonable [<a href="#rid1">1</a>]. Other approaches have also been utilized. In one series, treatment with oral prednisone 25 or 50 mg per day for one month seemed to slow hair loss in two patients with rapid hair loss [<a href="#rid18">18</a>]. </p><p>Systemic glucocorticoid therapy is associated with risk for a wide variety of serious adverse effects and should be approached with caution. Long-term treatment with systemic glucocorticoids is not advised, and patients should be transitioned to other treatments. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and <a class="local">'General approach'</a> above.)</p><p class="headingAnchor" id="H1046790778"><span class="h1">REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>Patients who fail to achieve disease stabilization with initial treatment options may try on other combinations of these therapies. For example, if a patient achieves only a partial response with a 5-alpha reductase inhibitor (5-ARI) given as initial treatment, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> could be added as an adjunctive therapy. If no additional improvement occurs after the addition of doxycycline, doxycycline could be stopped and replaced with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>. At least partial responses to 5-ARIs, hydroxychloroquine, or tetracyclines are expected within four months; we typically discontinue treatments that do not seem to have any benefit within this period.</p><p>The best approach to patients for whom this is insufficient is unclear. In this scenario, we typically discontinue the failed systemic therapies and prescribe an oral retinoid or immunosuppressive therapy. As with other therapies for FFA, efficacy of these interventions is unproven. In our experience, at least partial responses are usually evident within four months in patients who will respond to retinoid and immunosuppressive therapies.</p><p class="headingAnchor" id="H3122561971"><span class="h2">Oral retinoids</span><span class="headingEndMark"> — </span>Oral retinoids, such as <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, may be beneficial. In one retrospective study, 22 of 29 patients (76 percent) treated with isotretinoin (20 mg per day) and 8 of 11 patients (73 percent) treated with acitretin (20 mg per day) had no further progression of disease after 12 months of treatment, and similar proportions had no progression of disease 8 to 12 months after the discontinuation of treatment [<a href="#rid19">19</a>]. In the same study, 6 of 14 patients (43 percent) treated with <a class="drug drug_general" data-topicid="8447" href="/z/d/drug information/8447.html" rel="external">finasteride</a> (5 mg per day) achieved these endpoints. </p><p>The mechanisms through which retinoids might improve FFA are unclear; anti-inflammatory effects and promotion of normalization of antigen expression of follicular keratinocytes have been proposed [<a href="#rid18">18</a>].</p><p>Oral retinoids are teratogenic, and individuals of childbearing potential must avoid pregnancy during treatment. Pregnancy should also be avoided for one month after <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy and for three years after <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> therapy. (See  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/9250.html" rel="external">"Acitretin: Drug information"</a>.)</p><p class="headingAnchor" id="H1905252806"><span class="h2">Immunosuppressants</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (15 to 25 mg per week) and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (0.5 to 1 g twice daily) are occasionally used for refractory FFA based upon the immunosuppressive effects of these drugs. In one retrospective study, one of three patients treated with methotrexate achieved stabilization of disease [<a href="#rid20">20</a>]. In another retrospective study, one of five patients treated with mycophenolate mofetil responded (achievement of an 85 percent reduction in the Lichen Planopilaris Activity Index [LPPAI] score) and two had partial responses (25 to 85 percent reduction in the LPPAI score) after six months [<a href="#rid21">21</a>].</p><p><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are associated with risk for serious adverse effects. Adverse effects of these agents are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H4150227916"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>Multiple other agents have been reported as beneficial for FFA. However, limited experience and/or risk for adverse effects preclude recommendations for routine use. Examples include <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> (a peroxisome proliferator-activated receptor-gamma agonist) [<a href="#rid22">22</a>], <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> (an opioid antagonist with anti-inflammatory properties) [<a href="#rid23">23</a>], and <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> (a Janus kinase inhibitor) [<a href="#rid24">24</a>]. Pioglitazone has been studied more extensively in lichen planopilaris; however, efficacy of this drug for lichen planopilaris is also unclear. (See  <a class="medical medical_review" href="/z/d/html/15680.html" rel="external">"Lichen planopilaris", section on 'Other therapies'</a>.)</p><p>Procedural interventions have included treatment with an excimer laser or a carbon dioxide laser [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H910348769"><span class="h1">USE OF SUNSCREENS</span><span class="headingEndMark"> — </span>Although sunscreen use has been proposed as a risk factor for FFA, data are insufficient to confirm a causal relationship. Given the insufficient evidence and the known benefits of sunscreen use for skin cancer prevention, we do not advise our patients to cease use of sunscreens [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/128536.html" rel="external">"Frontal fibrosing alopecia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Pathogenesis'</a>.)</p><p>Hair regrowth in a patient with a clinical diagnosis of FFA after cessation of sunscreen use on the forehead has been reported [<a href="#rid28">28</a>]. The patient was also receiving other treatments.</p><p class="headingAnchor" id="H1014893406"><span class="h1">COSMETIC MEASURES</span></p><p class="headingAnchor" id="H1094130606"><span class="h2">Nonsurgical measures</span><span class="headingEndMark"> — </span>Some patients with hair loss secondary to FFA may desire options for camouflaging hair loss, such as hairpieces, wigs, and other products. Referral to a cosmetologist or other professional experienced with such products and techniques can be beneficial for these individuals.</p><p class="headingAnchor" id="H1847828611"><span class="h2">Hair transplantation</span><span class="headingEndMark"> — </span>Hair transplantation for the purpose of restoring hair in areas in patients with FFA should be approached with caution because of risk for poor long-term outcomes [<a href="#rid29">29,30</a>]. Although a retrospective study of 51 patients with FFA who underwent hair transplantation found that 42 (82 percent) reported satisfaction with the procedure, mean graft survival rates after one, two, three, and five years were 87 percent (n = 51), 71 percent (n = 51), 60 percent (n = 38), and 41 percent (n = 12), respectively [<a href="#rid29">29</a>]. The development of FFA following hair transplantation and face lift procedures has also been reported [<a href="#rid31">31</a>].</p><p>The optimal time for performance of hair transplantation is unclear. In general, hair transplantation is not advised for patients with cicatricial alopecia that has not been stabilized for at least one year because of the potential for the loss of transplanted hair upon reactivation of disease [<a href="#rid32">32,33</a>]. In addition, medical therapy for FFA is typically continued after hair transplantation in an attempt to minimize risk for recurrence of disease activity. Medical therapy can be tapered gradually as stability is maintained after the transplant procedure. Intermittent (eg, twice weekly) use of a high-potency topical corticosteroid or use of a topical calcineurin inhibitor has been suggested [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H832491533"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Data on the course of FFA without treatment are limited, and the course appears to vary among patients. The general course appears to involve a period of progressive hair loss followed by spontaneous disease stabilization after a widely variable period of time [<a href="#rid1">1,35</a>]. The author's experience suggests that disease activity for a period of around five years may be common.</p><p>Although partial hair regrowth has been reported with treatment, it is generally not expected given the cicatrizing nature of FFA. (See <a class="local">'Goals'</a> above.)</p><p>Prognostic factors for FFA are not established. The findings of a retrospective study that included 106 women with FFA treated with <a class="drug drug_general" data-topicid="8672" href="/z/d/drug information/8672.html" rel="external">dutasteride</a> and topical corticosteroids suggest that the pattern of hair loss may be an indicator of prognosis [<a href="#rid14">14</a>]. Eyebrow loss, eyelash loss, and facial papules are additional proposed poor prognostic factors [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1971473092"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Patients with FFA may benefit from close follow-up to assess responses to treatment. We typically see patients every 6 to 12 weeks until the disease is stabilized for at least 12 months. Subsequent clinical evaluations may occur every 6 to 12 months provided the patients remain asymptomatic and without sigs of progression of hair loss. More frequent evaluation may be necessary for patients continuing systemic maintenance treatments that require monitoring. Patients with stabilized disease who no longer require treatment can be instructed to return for re-evaluation if they experience recurrence of symptoms or hair loss.</p><p class="headingAnchor" id="H701286504"><span class="h1">RESOURCES FOR SUPPORT</span><span class="headingEndMark"> — </span>Hair loss secondary to FFA can be a significant psychologic stressor. Patients may benefit from access to support resources, such as the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.carfintl.org%2Fsupport%2F&amp;token=A4rNrjoOj2Gkzpl8CyA25viBeBtVxi8M%2FYLDKsGYgHAAO8liiCeRsx9oLluPB9Rf&amp;TOPIC_ID=110156" target="_blank">Cicatricial Alopecia Research Foundation</a>.</p><p class="headingAnchor" id="H2418202906"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Frontal fibrosing alopecia (FFA) is a lymphocytic cicatricial (scarring) alopecia that classically presents with progressive regression of the frontal hairline  (<a class="graphic graphic_picture graphicRef127007 graphicRef127013 graphicRef101628 graphicRef90010" href="/z/d/graphic/127007.html" rel="external">picture 1A-D</a>). FFA may represent a subtype of lichen planopilaris. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The primary goal of treatment of FFA is disease stabilization (cessation of progression of hair loss). Additional beneficial effects include resolution of other signs of disease activity, including symptoms (pruritus, pain, burning) and perifollicular erythema and scale. Regrowth of hair lost secondary to FFA is not expected. (See <a class="local">'Goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment for disease stabilization can be performed through serial measurements of hairline recession and clinical photographs. The response of other findings suggestive of disease activity can be assessed through the patient history and physical examination. (See <a class="local">'Assessment of response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with FFA and active progression of hair loss or other findings suggestive of active disease (symptoms or perifollicular erythema or scale), we suggest treatment rather than observation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For asymptomatic patients with a confirmed absence of recent progression of hair loss (eg, clinical documentation supportive of stable disease for at least 12 months) who also lack other findings suggestive of active disease, we suggest <strong>not</strong> initiating treatment specifically for FFA (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment for concomitant disorders that may also cause hair loss, such as androgenic alopecia, can still be initiated. Close clinical follow-up for recurrence of disease activity should be implemented. (See <a class="local">'Who to treat'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with active progression of hair loss, we suggest a combination of local and systemic treatment rather than local treatment alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Our typical initial regimen includes a high-potency topical corticosteroid, periodic intralesional corticosteroid injections, topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>, and a systemic therapy (5-alpha reductase inhibitor [5-ARI], <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, or <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> class antibiotic). Selection among these systemic therapies is based upon consideration of patient-specific contraindications and preferences. Patients presenting with rapid progression of hair loss may benefit from a course of systemic glucocorticoid therapy. (See <a class="local">'General approach'</a> above and <a class="local">'Rapidly progressing disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who continue to have progression of hair loss despite standard systemic treatments (5-ARI, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, and/or <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> class antibiotics), we suggest oral retinoid or immunosuppressive therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Common initial options include <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil. Other treatments have also been utilized. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sunscreen use has been proposed as a risk factor for FFA; however, data are insufficient to confirm a causal relationship. We suggest that patients with FFA do <strong>not</strong> avoid sunscreen use (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Use of sunscreens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hair transplantation has been utilized in an attempt to restore hair in areas of permanent alopecia. Hair transplantation for FFA should be approached with caution. In general, hair transplantation is not advised for patients with FFA that has not been stabilized for at least one year.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: A review and clinical approach. J Am Acad Dermatol 2019; 81:568.</a></li><li><a class="nounderline abstract_t">Chiang C, Sah D, Cho BK, et al. Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol 2010; 62:387.</a></li><li><a class="nounderline abstract_t">Saceda-Corralo D, Moreno-Arrones ÓM, Fonda-Pascual P, et al. Development and validation of the Frontal Fibrosing Alopecia Severity Score. J Am Acad Dermatol 2018; 78:522.</a></li><li><a class="nounderline abstract_t">Rallis E, Gregoriou S, Christofidou E, Rigopoulos D. Frontal fibrosing alopecia: to treat or not to treat? J Cutan Med Surg 2010; 14:161.</a></li><li><a class="nounderline abstract_t">Banka N, Mubki T, Bunagan MJ, et al. Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up. Int J Dermatol 2014; 53:1324.</a></li><li><a class="nounderline abstract_t">Iorizzo M, Tosti A. Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment. Am J Clin Dermatol 2019; 20:379.</a></li><li><a class="nounderline abstract_t">Heppt MV, Letulé V, Laniauskaite I, et al. Frontal Fibrosing Alopecia: A Retrospective Analysis of 72 Patients from a German Academic Center. Facial Plast Surg 2018; 34:88.</a></li><li><a class="nounderline abstract_t">Donovan JC, Samrao A, Ruben BS, Price VH. Eyebrow regrowth in patients with frontal fibrosing alopecia treated with intralesional triamcinolone acetonide. Br J Dermatol 2010; 163:1142.</a></li><li><a class="nounderline abstract_t">Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol 2014; 70:670.</a></li><li><a class="nounderline abstract_t">Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150:186.</a></li><li><a class="nounderline abstract_t">Lachgar S, Charvéron M, Bouhaddioui N, et al. Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells. Arch Dermatol Res 1996; 288:469.</a></li><li><a class="nounderline abstract_t">Tziotzios C, Fenton DA, Stefanato CM, McGrath JA. Finasteride is of uncertain utility in treating frontal fibrosing alopecia. J Am Acad Dermatol 2016; 74:e73.</a></li><li><a class="nounderline abstract_t">Murad A, Bergfeld W. 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update. J Eur Acad Dermatol Venereol 2018; 32:1385.</a></li><li><a class="nounderline abstract_t">Moreno-Arrones OM, Saceda-Corralo D, Fonda-Pascual P, et al. Frontal fibrosing alopecia: clinical and prognostic classification. J Eur Acad Dermatol Venereol 2017; 31:1739.</a></li><li><a class="nounderline abstract_t">Seale LR, Eglini AN, McMichael AJ. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review. J Drugs Dermatol 2016; 15:414.</a></li><li><a class="nounderline abstract_t">Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.</a></li><li><a class="nounderline abstract_t">Strazzulla LC, Avila L, Li X, et al. Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases. J Am Acad Dermatol 2018; 78:203.</a></li><li><a class="nounderline abstract_t">Kossard S, Lee MS, Wilkinson B. Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. J Am Acad Dermatol 1997; 36:59.</a></li><li><a class="nounderline abstract_t">Rakowska A, Gradzińska A, Olszewska M, Rudnicka L. Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases. J Drugs Dermatol 2017; 16:988.</a></li><li><a class="nounderline abstract_t">Ladizinski B, Bazakas A, Selim MA, Olsen EA. Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. J Am Acad Dermatol 2013; 68:749.</a></li><li><a class="nounderline abstract_t">Samrao A, Chew AL, Price V. Frontal fibrosing alopecia: a clinical review of 36 patients. Br J Dermatol 2010; 163:1296.</a></li><li><a class="nounderline abstract_t">Mesinkovska NA, Tellez A, Dawes D, et al. The use of oral pioglitazone in the treatment of lichen planopilaris. J Am Acad Dermatol 2015; 72:355.</a></li><li><a class="nounderline abstract_t">Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris. J Drugs Dermatol 2017; 16:1140.</a></li><li><a class="nounderline abstract_t">Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: A case series. Dermatol Ther 2018; 31:e12656.</a></li><li><a class="nounderline abstract_t">Navarini AA, Kolios AG, Prinz-Vavricka BM, et al. Low-dose excimer 308-nm laser for treatment of lichen planopilaris. Arch Dermatol 2011; 147:1325.</a></li><li><a class="nounderline abstract_t">Cho S, Choi MJ, Zheng Z, et al. Clinical effects of non-ablative and ablative fractional lasers on various hair disorders: a case series of 17 patients. J Cosmet Laser Ther 2013; 15:74.</a></li><li><a class="nounderline abstract_t">Robinson G, McMichael A, Wang SQ, Lim HW. Sunscreen and frontal fibrosing alopecia: A review. J Am Acad Dermatol 2020; 82:723.</a></li><li><a class="nounderline abstract_t">Cranwell WC, Sinclair R. Frontal fibrosing alopecia: Regrowth following cessation of sunscreen on the forehead. Australas J Dermatol 2019; 60:60.</a></li><li><a class="nounderline abstract_t">Vañó-Galván S, Villodres E, Pigem R, et al. Hair transplant in frontal fibrosing alopecia: A multicenter review of 51 patients. J Am Acad Dermatol 2019; 81:865.</a></li><li><a class="nounderline abstract_t">Liu YS, Jee SH, Chan JL. Hair transplantation for the treatment of lichen planopilaris and frontal fibrosing alopecia: A report of two cases. Australas J Dermatol 2018; 59:e118.</a></li><li><a class="nounderline abstract_t">Chiang YZ, Tosti A, Chaudhry IH, et al. Lichen planopilaris following hair transplantation and face-lift surgery. Br J Dermatol 2012; 166:666.</a></li><li><a class="nounderline abstract_t">Unger W, Unger R, Wesley C. The surgical treatment of cicatricial alopecia. Dermatol Ther 2008; 21:295.</a></li><li><a class="nounderline abstract_t">Dahdah MJ, Iorizzo M. The Role of Hair Restoration Surgery in Primary Cicatricial Alopecia. Skin Appendage Disord 2016; 2:57.</a></li><li><a class="nounderline abstract_t">Mendes-Bastos P, Camps-Fresneda A. Hair Transplantation for Frontal Fibrosing Alopecia: Part of the Solution? Actas Dermosifiliogr 2016; 107:3.</a></li><li><a class="nounderline abstract_t">Gamret AC, Potluri VS, Krishnamurthy K, Fertig RM. Frontal fibrosing alopecia: efficacy of treatment modalities. Int J Womens Health 2019; 11:273.</a></li><li><a class="nounderline abstract_t">Imhof RL, Chaudhry HM, Larkin SC, et al. Frontal Fibrosing Alopecia in Women: The Mayo Clinic Experience With 148 Patients, 1992-2016. Mayo Clin Proc 2018; 93:1581.</a></li></ol></div><div id="topicVersionRevision">Topic 110156 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953702" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Medical therapy for frontal fibrosing alopecia: A review and clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061052" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28947289" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Development and validation of the Frontal Fibrosing Alopecia Severity Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20642984" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Frontal fibrosing alopecia: to treat or not to treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24738979" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30659454" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29278862" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Frontal Fibrosing Alopecia: A Retrospective Analysis of 72 Patients from a German Academic Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716217" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Eyebrow regrowth in patients with frontal fibrosing alopecia treated with intralesional triamcinolone acetonide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508293" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Frontal fibrosing alopecia: a multicenter review of 355 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996087" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Minoxidil: mechanisms of action on hair growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8844127" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inhibitory effects of bFGF, VEGF and minoxidil on collagen synthesis by cultured hair dermal papilla cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979373" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Finasteride is of uncertain utility in treating frontal fibrosing alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29524253" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426907" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Frontal fibrosing alopecia: clinical and prognostic classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050696" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Side Effects Related to 5α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26992838" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241787" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996262" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29036252" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375454" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20698851" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Frontal fibrosing alopecia: a clinical review of 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25592345" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of oral pioglitazone in the treatment of lichen planopilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141063" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30264512" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tofacitinib for the treatment of lichen planopilaris: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106124" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Low-dose excimer 308-nm laser for treatment of lichen planopilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464363" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical effects of non-ablative and ablative fractional lasers on various hair disorders: a case series of 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31654665" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sunscreen and frontal fibrosing alopecia: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29896853" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Frontal fibrosing alopecia: Regrowth following cessation of sunscreen on the forehead.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31350039" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hair transplant in frontal fibrosing alopecia: A multicenter review of 51 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736812" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hair transplantation for the treatment of lichen planopilaris and frontal fibrosing alopecia: A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985326" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lichen planopilaris following hair transplantation and face-lift surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18715299" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The surgical treatment of cicatricial alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27843925" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Role of Hair Restoration Surgery in Primary Cicatricial Alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341071" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hair Transplantation for Frontal Fibrosing Alopecia: Part of the Solution?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31118828" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Frontal fibrosing alopecia: efficacy of treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30392542" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Frontal Fibrosing Alopecia in Women: The Mayo Clinic Experience With 148 Patients, 1992-2016.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
